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Introduction
Skin cancer in the United States is a large and growing public health concern
with an estimated one million new cases diagnosed each year. As a result, there are
many modalities available for use in prevention and treatment. The efficacy of natural
alternatives to prevent and treat skin cancer has become an area of great interest that is
relatively unknown to physicians. Despite this, the US population has embraced
complementary medicine alternatives, often as a replacement for traditional allopathic
therapies, in many areas including skin cancer. For public health advocates,
knowledge of the effectiveness of these alternative therapies and the evidence that
support these remedies is essential.
This paper will discuss the scope ofthe skin cancer problem in the US
including epidemiology and current methods of screening and prevention. Following
this will be an extensive review of the most current information regarding the
prevention and treatment of skin cancer through dietary modification and topical
application of antioxidants, vitamins, and herbal supplements. The results of placebo-
controlled randomized clinical trails, large human cohort studies and case-control
studies have been emphasized to provide an evidence-based approach toward
improving the health of our population.
Epidemiology of Skin Cancer
Incidence
Ofthe three major types of skin cancer, basal cell carcinoma (BCC) accounts
for approximately 80%, squamous cell carcinoma (SCC) for approximately 16%, and
cutaneous malignant melanoma (MM) for approximately 4%. Of skin cancer deaths,
however, nearly 90% result from malignant melanoma. On average in the United
States, one person dies of melanoma every hour. Early detection and education are
levering-off or decreasing the incidence, morbidity, and mortality rates of all forms of
skin cancer.
Malignant Melanoma was the sixth most common cause ofnew cancer cases in
the United States for 1999 among males and seventh among females, accounting for
4% and 3%, respectively.2 In the United States, MM is more common than any
noncutaneous cancer among 25-29 year olds. Epidemiologic data is more precise for
MM than nonmelanoma skin cancer (NMSC) because the diagnosis ofthe former but
not the latter is routinely reported to tumor registries.3
Marked increases in the incidence ofMM occurred from the mid-1960s to the
mid-1990s. It has been estimated that the incidence in Caucasians increased from 3%
to 7% during this 30-year period.4 Calculations based on data from the Surveillance,
Epidemiology, and End Results (SEER) program ofthe National Cancer Institute,
showed an increase in the incidence of MM in the United States of 120.5% from 1973
to 1994. However, increased education and awareness appear to result in earlier
detection and a greater increase in thin rather than thick tumors. In the United States,
a 500% increase from the period of 1973-77 to 1983-87 was reported in the diagnosis
of in situ MM compared to a 52% increase in the diagnosis of invasive MM.6
Stabilization or decrease of incidence rates of MM have been reported over
the past few years. For example, in the United States from 1990 to 1994, rates
stabilized or declined for females younger than 60 years old and males younger than
50 years old, while rates increased for older age groups,s The incidence in the United
States of invasive tumors decreased two consecutive years from 14.1 per 100,000 in
1991 to 13.8 per 100,000 in 1993.6
Risk Factors
Skin cancer is exceedingly more common in Caucasians than other races,
although NMSC not infrequently affects Hispanics and acral lentiginous melanoma is
the most common type ofMM affecting Asians and blacks. All forms of skin cancer
are more common in men than women. NMSC most commonly affects chronically
sun-exposed sites including the head and neck, trunk, and upper extremities. MM
most commonly affects sites of intermittent intense sun exposure, the trunk in men and
the lower extremity in women. Risk factors for skin cancer include history of
significant sun exposure; light colored eyes, skin, and hair; tendency to sunburn easily
and tan poorly; personal or family history of skin cancer; male sex; advancing age;
and immunodeficiency, resulting from status post organ transplantation or human
immunodeficiency virus infection. There are additional unique risk factors for the
development ofMM such as a personal history of atypical moles or multiple moles.
Prognosis
The prognosis for BCC is excellent. Only 0.0028% ofBCCs metastasize.
Metastatic disease is more common in men than women and usually arises from large
neglected tumors. Five year survival for metastatic BCC is less than 33%.7 Patients
with basal cell nevus syndrome, a rare sporadic or autosomal dominant condition
characterized by multiple BCCs, jaw cysts, palmoplantar pits, and a wide variety of
other anomalies, may develop locally invasive or metastatic tumors.
Approximately 5% of SCCs metastasize within 5 years. Risk factors for
metastases include depth greater than 4 mm; diameter greater than 2 cm; poorly
differentiated histology; perineural, vascular, and lymphatic invasion; tumors located
on the lip; tumors arising in osteomyelotic foci, bums, and scars; immunodeficiency.
Five year survival is approximately 30% for patients with metastatic SCC.7 In 1998,
there were approximately 1,200 deaths from SCC.
In the United States, nearly 90% of skin cancer deaths are from MM and 7,300
deaths from MM were estimated for 1999. Mortality rates for MM rose 38.9% from
1973 to 1994.s Mortality rates are greater for males than for females and for older
than younger individuals. Mortality rates stabilized or decreased for all groups from
1990-94, except for men 70 years or older and women 60-69 years old.s Thicker
tumors are associated with greater risk for advanced disease and mortality. Five year
survival is 93-100% for tumors < 0.76 mm in depth and 50% or less for tumors > 4
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mm. For the period from 1989 to 1994, the five year survival for CMM in the United
States was 88% for white patients and 69% for black patients.2
Traditional Methods of Skin Cancer Prevention
Primary prevention of skin cancer involves education of the population to
actively attempt to reduce the amount oftheir ultraviolet exposure. This includes the
use of daily sunscreen application and the use of clothing and hats to prevent
unnecessary sunlight exposure. Secondary prevention involves early detection of
changes in the skin through specific screening methods to decrease morbidity and
mortality of skin cancer.
Since BCC is so rarely fatal, early detection impacts insignificantly on
mortality. However, early diagnosis ofBCC is effective in minimizing local tissue
destruction by the tumor and allows for less complex surgical excision ofthe tumor,
decreased size of the surgical defect, and improved cosmesis. Similarly, early
detection of SCC reduces morbidity of the disease. Additionally, early detection of
SCC is likely to be associated with decreased risk for regional and distant metastatic
disease and improved mortality rates.
Early detection ofMM is considered essential because ofthe high mortality
rate and the strong relationship between tumor thickness and mortality. MMs
diagnosed during periodic surveillance examinations are more likely to be smaller and
thinner than those diagnosed at first presentation.9 Skin self-examination has been
suggested to reduce the mortality by 63% by reducing the incidence of CMM and the
risk of advanced disease.
Physical examination ofthe skin is the method by which individuals are
screened for skin cancer. Biopsy submitted to a dermatopathology laboratory is
essential for histologic confirmation of suspicious lesions. History of risk factors for
skin cancer and ofnew, changing, or symptomatic lesions aids the screening process.
Total body photography ofpatients with atypical and/or multiple melanocytic nevi,
epiluminescence microscopy, and computerized digital imaging are tools the
subspecialist may utilize as adjuncts to the physical examination. Detection in the
peripheral blood of biochemical markers for CMM is an experimental technique which
may be most useful in identifying advanced tumors and predicting response to medical
therapyl
Mechanisms of Skin Cancer Development
The biochemical mechanisms responsible for cell injury and cell death are
complicated and the pathways are multiple and overlapping. We will focus on the
roles played by two major contributors to cellular damage, oxygen-derived free
radicals and ultraviolet radiation, in mediating the pathological changes manifested
clinically as NMSC and melanoma.
Reactive Oxygen Species
With a single unpaired electron in their outer orbit, free radicals or reactive
oxygen species (ROS) are highly unstable chemical species that can damage lipids,
proteins, and nucleic acids. Free radicals also initiate autocatalytic reactions that
convert the molecules they interact with into additional free radicals, lz Reactive
oxygen species can be generated within cells as a byproduct of mitochondrial
respiration in the reduction ofmolecular oxygen to water, the absorption ofultraviolet
light, and the donation or acceptance of free electrons by transitional metals. These
processes generate hydrogen peroxide, superoxide anion radicals, and hydroxyl ions.
Nitric oxide (NO), an important chemical mediator produced by endothelial cells,
macrophages, and neurons, can also act as free radicals. NO can be converted to
highly reactive species such as the peroxynitrite anion (ONOO), NO2 and NO-
Cellular damage occurs when free radicals, in the presence of oxygen, attack
membrane lipids yielding peroxides, which serve as autocatalytic propagators of free
radical reactions.
Cells have an endogenous defense system to combat free radical induced
cellular damage and death. There is a delicate balance between the generation of free
radicals and the free radical scavenging systems. As unstable chemical species, many
free radicals decay spontaneously. Additionally, there are several enzymatic and non-
enzymatic pathways that help to deactivate these reactive oxygen species. Free
radicals such as hydrogen peroxide, superoxide, and hydroxyl radicals are detoxified
by catalase, superoxide dismutase, and glutathione peroxidase, respectively. The non-
enzymatic pathway includes antioxidants such as vitamins that neutralize free radicals.
When free radical formation exceeds free radical termination, cells experience
oxidative stress leading to pathological transformation.
Ultraviolet Radiation
The two major pathological effects of ultraviolet radiation are photodamage
leading to premature aging of the skin and skin cancer. It has been postulated that
ultraviolet carcinogenesis consists of two events: first, the transformation of a skin cell
to a neoplastic form and second, UVB-induced immunosuppression.4 Ultraviolet
radiation, specifically UVB, can cause direct damage to DNA such as the formation of
pyrimidine dimers between adjacent pyrimidine bases on the same DNA strand,
single-stranded breaks, and DNA-protein cross links3o UV radiation also causes
mutations in oncogenes, such as ras, and tumor suppressor genes, such as p53. The
ras family ofproto-oncogenes mediates cell-signaling pathways for many growth
factor receptors. 5 Ras may play an important role in early skin carcinogenesis as
UVB rays have caused "signature mutations" in ras genes in some human basal cell
carcinomas (BCCs). The tumor suppressor gene p53 serves as a filter for cells that
have acquired mutations in the skin. The p53 gene conveys its tumor suppressive
effects by initiating apoptosis ofmutated progeny cells.s Following exposure to UV
radiation there is a transient increase in p53 levels in the skin.s The elimination of
mutated keratinocytes via the p53 apoptotic pathway prevents the formation of
mutated keratinocyte cell colonies. This inducible reparative ability may be due to the
DNA fragment thymidine dinucleotide. This DNA fragment has been shown to
increase the rate of repair ofDNA ultraviolet damage by 2 or 3 fold.6 It is thought
that the induction ofDNA repair mechanisms is related to the up regulation ofthe
tumor suppressor gene p53. Cutaneous levels ofp53 continue to persist several days
after UV exposure.6 When the p53 gene becomes mutated, as a result ofUVB
exposure, cells fail to undergo programmed cell deathis Indeed, squamous cell
carcinomas have been found to have a high percentage ofp53 mutations. 7
Additionally, UV radiation has been linked to cutaneous immunosuppression
resulting in both a decrease in surveillance for UV induced tumor antigens and
depressed cell mediated contact hypersensitivity response (CHS). Animal studies
have shown that UV radiation exposure, prior to the application ofknown topical
mutagens such as dinitrochlorobenzene (DNCB), decreases the normal skin response
to the DNCB antigen. This subdued response includes a decrease in skin erythema,
edema, and induration at the site of application for 2 to 3 days. 15 It is thought that this
immune reaction may be a result of the UV induced disturbance of the communication
between the antigen presenting cells of the skin, the Langerhans cells, and antigen
specific T-lymphocytes. is
Dietary and Topical Antioxidant Effects on NMSC
Retinoids
The term retinoid encompasses both naturally occurring molecules that are
present in low levels in the peripheral blood and also synthetically derived compounds
with biological activities of vitamin A or retinol. Natural sources of vitamin A include
liver, egg yolk, butter, fish, yellow and orange fruits and vegetables including carrots,
tomatoes, apricots, and cantaloupe and green leafy vegetables. Vitamin A and its
metabolic derivatives, retinaldehyde and retinoic acid, are fat-soluble molecules
necessary for growth, differentiation, and maintenance of epithelial tissues.
Retinoids can be thought of as both vitamins and hormones. They are vitamins
in that retinol is not synthesized from the body and must be obtained through the diet
and they are hormones in that the body transforms retinol into substrates (9-cis RA
and tRA) which bind to nuclear receptors and serve as signaling molecules to regulate
epithelial cell differentiation, proliferation, growth, and metabolism.9 Cell growth,
proliferation, differentiation and cell death are influenced by DNA transcription via
the binding of retinoids to both the retinoi.d acid receptors (RARs) and the retinoid X
receptors (RXRs).
In order to decrease the toxic effects ofvitamin A and utilize its more
biologically active components, the naturally occurring molecule must be modified for
therapy. Three classes of synthetic retinoids are used today which include"
nonaromatic retinoids such as tretinoin and isotretinoin, monoaromatic retinoids such
10
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as etretinate and acitretin, and polyaromatic retinoids such as adapalene and
21tazarotene.
Two cell line studies by Moon et al. in 1983 and 1992z’23 have shown the
influence retinoids have on cell growth and differentiation and their suppressive
effects on carcniogenesis of epithelial rumors and other cancer cell lines. Earlier
studies involving the chemoprotective effects of retinoids in mice and human clinical
reports emphasized their effectiveness for the prevention ofchemical and UV light
induced skin cancer.24’25’26 Unfortunately, the human clinical studies consisted of
small sample populations and the high doses of retinoids used had significant side
effects.27 Larger studies involving oral administration of lower doses of retinoids
(isotretinoin) resulted in poor chemoprevention against BCCs.28 Subsequently,
retinoids have been more extensively studied in the chemoprevention ofNMSC.
Moon et al., 199729 conducted a randomized placebo-controlled 5 year clinical
trial which examined the use of vitamin A (25,000 U) vs. placebo in 2,297 patients
with a moderate risk of skin cancer development (i.e., a history of>10 actinic
keratoses but fewer than 3 BCCs or SCCs). They found that patients who were treated
with vitamin A had fewer SCCs than the placebo group; however, this was not the
case for BCCs.
Several cohort and case-control studies have been undertaken during the last 5
years to examine the relationship between retinoids and chemoprevention. The van
Dam et al. 200030 study, in which a large prospective cohort ofmen was evaluated in
terms ofthe relationship between their respective diets and their subsequent
development ofBCC, did not show a significant difference between those individuals
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that consumed higher amounts ofretinols in their diet than those who did not. This
finding is consistent with other large randomized trials including Levine et al. 199731
in which 400 subjects with a previous history of4 or more skin cancers were treated
with isotretinoin 10-15mg/day, vitamin A 25,000 U, or placebo. No significant
difference between the treatment groups or controls was detected. T-hese studies both
support the evidence obtained by Tangrea et al., 199228 whose multicenter study
examining the possible benefit of low dose isotretinoin (10mg/day vs. placebo for 3
years) on the prevention ofBCC showed no difference between the study groups.
In addition to these larger best evidence studies, several smaller trials have
illustrated the potential role of oral retinoids in the prevention of NMSC.32’3
However, the most significant results were seen in niche treatment protocols for
patients with a higher susceptibility to skin neoplasms. For example, patients with
xeroderma pigmentosum treated with isotretinoin for 2 years had an average reduction
of63% in the number of skin cancers over a 2-year period as compared to no previous
treatment.33 More recently, however, DiGiovanna 199834 studied whether isotretinoin
could be effective in chemoprevention of skin cancer in high-risk patients with
xeroderma pigmentosum. A small sample ofpatients (of 7 patients enrolled, 5 were
able to complete the study) used isotretinoin at 2mg/kg/day for 2 years. He found that
there was a 63% reduction in the number of cancers these patients developed as
compared with the 2 years prior to therapy. However, upon discontinuation of
isotretinoin therapy, skin neoplasms developed within 2 to 3 months. These findings
suggest that the chemopreventive effect of isotretinoin is limited to the active
treatment period.
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The development of skin cancer in immunosuppressed individuals after
transplantation is particularly significant in areas of the world with high levels of
ultraviolet exposure. As medical technology rapidly advances, organ transplantation
and sustained immune suppression is increasingly more common. Incidences of
NMSC in renal transplant recipients in Australia increased exponentially over a >9
year period" 3% within the first year, 25% at 5 years and 44% at 9 or more years.34’35
The use of retinoids as a preventative therapy for transplant recipients has been
explored in several studies. For example, Bavinck et al., 19956 conducted a double-
blind placebo controlled study in which acitretin 30mg/day or placebo pills were given
to 38 renal transplant recipients for 6 months. The patients who received the acitretin
developed significantly fewer SCCs than the placebo group alone (P=0.01), suggesting
that acitretin may offer a chemoprotective effect against skin neoplasms.
Small studies have also been undertaken to examine the combined therapeutic
effect of isotretinoin and calcitriol to treat and prevent multiple early NMSCs.
Calcitriol (0.5 to 1.0 ug/kg/day) and isotretinoin (0.3 to 0.5 mg/kg/day) were given to
11 patients over a 15-month period. The authors reported a decrease in the size of
most ofthe actinic kerotoses of the 11 patients and a decrease in size of an early SCC
in one patient.7 This study was both small and without placebo controls so its results
may be due to chance alone. The data suggest, however, that the use of synergistic
vitamin derivatives may offer possible future tumor prevention if a larger number of
patients and a placebo-controlled methodology is employed.
The induction ofmultiple squamous cell carcinomas following long term
PUVA treatments for psoriasis has been well established.8’9 It has been proposed
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that combination therapy of retinoids and PUVA may reduce the risk of skin cancer
and other skin damage associated with PUVA treatment.4 Acitretin, the active
metabolite of etretinate, has recently been approved in this country for the treatment of
psoriasis. As a monotherapy, acitretin is an effective method for treatment of pustular
and erythrodermic psoriasis but for plaque psoriasis, it is best used as an adjuvant
therapy with UVB or with PUVA.4 Combining acitretin with PUVA results in a
more rapid clearing of psoriatic plaques at lower doses of both treatment modalities
than either therapy alone.4 A case report of a patient treated for over 14 years with
PUVA therapy and topical steroids developed 34 SCC in total, 21 ofwhich developed
with PUVA and cyclosporin adjuvant therapy. An inhibition oftumor formation
occurred with the onset of acitretin therapy (60 mg/day) and continuous treatment with
acitretin has kept the patient tumor free for 4 years. Acitretin may therefore have
some value in preventing the occurrence of SCCs in patients treated with long term
PUVA. As acitretin thins the stratum corneum and epidermis, however, lower doses
ofUVB or UVA should be used as there is an increased sensitivity to ultraviolet light
resulting in burning.42
In summary, review ofthe current randomized clinical trials, large human
cohort and case-control studies does not illustrate a beneficial effect of either natural
dietary retinoids or synthetic retinoid supplementation for treatment or prevention of
BCCs or SCCs in the general patient population. In contrast to these larger best
evidence studies, several small trials have demonstrated the potential role for oral
retinoids in preventing NMSCs in patients with a higher susceptibility to skin
neoplasms such as patients undergoing concurrent immunosuppressive treatment
15
status post transplantation, patients with xeroderma pigmentosum, or patients being
treated with PUVA therapy for psoriasis. Unfortunately, large cohort and randomized
clinical trials have not yet been published on the relationship between retinoids,
NMSC, and these specific conditions.
Selenium
Selenium is found in fish, shellfish, red meat, egg yolks, chicken, garlic, tuna,
bread, cereal, mushrooms, asparagus and grain products. This trace element is
necessary for the function of the detoxifying enzyme glutathione peroxidase, which
helps to reduce the presence of highly reactive hydroxyl free radicals. It is thought
that these hydroxyl radicals attack DNA and cause mutations.43 Studies in mice have
shown that increased levels of dietary selenium provide protection against ultraviolet
induced skin tumors.44 Stewart et al., 199645 examined whether the combined use of
antioxidant nutrients such as selenium, Vitamin C, and Vitamin E decreased the level
of UVB induced oxidative damage to mouse keratinocytes as indicated by the
formation ofthe DNA adduct, 8-hydroxydeoxyguanosine (8OHdG). The
investigators’ goal was to determine whether antioxidant supplementation could
enhance the rate ofDNA repair ofUVB induced lesions. When keratinocytes were
incubated for 2 days with the nutrients a significant decrease in the amount of
oxidative damage was observed, as measured by a decrease in the number of 8OHdG
adducts per pretreated cell. By increasing the concentration of antioxidants in the
culture medium during cell growth there was a significant decrease in the DNA
oxidative damage that occurred as a consequence ofUVB irradiation.
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In human trials, serum selenium levels were found to be predictive of future
cancer risks in humans.6 A case control study by Clark et al., 198447 illustrated that
skin cancer patients that were otherwise healthy had significantly lower mean serum
selenium values than did controls. The most powerful study evaluating the effects of
selenium supplementation for cancer prevention in patients with known carcinoma of
the skin was conducted as a large, multicenter, double-blind, randomized, placebo-
controlled trial by Clark et al., 1996.4 The purpose of this study was to determine
whether the incidence of cancer could be decreased with the nutritional
supplementation of selenium. A total of 1312 patients, with a previous history ofBCC
or SCC, from selenium deficient areas ofthe eastern United States, were randomized
to either an oral selenium supplementation group (200ug/day) or a placebo group and
followed over a 4.5-year period. They found that the selenium treated group did not
have a significantly different incidence of either BCC or SCC. Thus they concluded
that selenium supplementation does not protect against the development of BCCs or
SCCs in the skin. This study did show, however, a 40% reduction in non-cutaneous
cancers in the group receiving selenium. Although the number of cases was small,
treatment with selenium was shown to reduce the incidence of cancers involving the
lung, colon/rectum and prostate as well as reducing the mortality of lung cancer.
Interestingly, breast cancer, bladder cancer, and leukemia-lymphoma were more
frequent in the selenium group than in the placebo group. However, none of these
differences was statistically significant.4
In conclusion, while oral administration of selenium has been shown to reduce
the incidence of several types of cancer, its direct effect in reducing BCC or SCC
17
incidence has not been demonstrated in human randomized clinical trials to date. The
protective effect of other preparations of selenium such as topical applications has not
been examined in a systematic way and may present a possibility for future studies.
/f-carotene
fl-carotene is available in food sources such as orange and red vegetables,
carrots, tomatoes, beets, and berries. There are more than 600 carotenoids in the food
supply but some of the most common are ]3-carotene, alpha-carotene, lycopene,
crocetin, and fucoxanthin27. In the last decade, studies have attempted to establish a
relationship between NMSC risk and ]3-carotene, the most well studied carotene.3’49
,/3-carotene has been postulated to reduce free radical damage ofDNA after ultraviolet
exposure,s Indeed, mice studies have demonstrated a decrease in the number of
chemically and UV light induced skin cancers as a result of oral supplementation of 13-
carotene.S 1,52
Data in humans showed that oral 13-carotene supplementation reduced
ultraviolet immunosuppression52. However, when Noonan et al., 1996 examined
dietary ]7-carotene and ultraviolet-induced immunosuppression, they were not able to
show that supplementing the diet of mice with oral 3-carotene altered their
susceptibility to UV immune suppression3. Results of these animal and small human
studies on [-carotene and NMSC have not demonstrated consistent results.
In a large, randomized, placebo-controlled trial, 1805 patients with recent
NMSC were given 50 mg of fl-carotene/day for up to 5 years.4 Although the median
plasma fl-carotene levels increased to 8.5 times baseline, no significant effect was
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found on the incidence of the first new NMSC. More recently, researchers have
embarked on several large human cohorts and randomized controlled trials examining
the relationship between [3-carotene supplementation and the prevention ofBCC and
SCC. Van Dam et al., 200030 examined the role of fat intake, antioxidant nutrients,
retinol, folate and vitamin D as possible preventitive agents against the formation of
BCC in a cohort study of 43,217 men followed over an 8-year time period. At the
onset of the study, the dietary habits of the male subjects were assessed via validated
food frequency questionnaires. Analysis of their data, which related carotene intake
in 1986 to BCC occurrence between 1990 and 1994 revealed that alpha-carotene, was
associated with a slightly lower risk ofBCC (i.e., P=0.01 with a 95% confidence
interval and a relative risk of 0.88).
-carotene illustrated a less significant effect, P=
0.03 and a relative risk of 0.81. However, the investigators concluded that, overall,
the findings do not support the hypothesis that diets low in fat or high in specific
vitamins lower the risk ofBCC. The findings ofthe van Dam et al. 200030 study are
similar to that of the Hunter et al., 19924 large prospective cohort study in which diet
(vitamins C, D, E and ]3-carotene) and the risk ofBCC development was evaluated in
female nurses over a 4 year follow up period with no conclusive results.
Green et al. 1999,6 in a randomized placebo-controlled trial, examined the
relationship between the use of daily sunscreen application and [3-carotene
supplementation in order to prevent BCCs and SCCs. Using prospective design 1,383
patients were followed over a 4.5-year period. The patients were split into four groups
accordingly: daily sun protection factor 15 sunscreen application and 30mg/day of oral
-carotene; sunscreen plus placebo pills, 30 mg/day of
-carotene only; and placebo
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pills only. Results of this study illustrated that in terms ofBCCs there were no
statistically significant differences between the patients who used daily sunscreen and
those who did not. Using daily sunscreen did, however, have a significant effect on
the number of SCCs patients developed in this cohort. There was no significant
difference between the group that took oral fl-carotene vs. placebo pills for both BCC
and SCC. These findings are consistent with an older placebo-controlled clinical trial
in which 1,805 patients with a previously diagnosed NMSC were given either 50mg of
oral/7-carotene or daily placebo pills over a 5-year period. Neither the total number
ofnew NMSC nor the time period in which the patients developed a new NMSC was
54
significantly different between the two groups.
In conclusion, a systematic review of the large cohort and randomized clinical
trials illustrates that no chemopreventive effect was demonstrated with either normal
dietary consumption or oral supplementation of [-carotene.’4’s’6 Although
researchers who argue for the beneficial effects of betacarotene supplementation
suggest that these benefits may only be appreciated over a lifetime of use, this idea is
difficult to examine due to the length of study time that would be required.
Synergy of the Antioxidants on NMSC
Substantial evidence indicates that the antioxidant system ofthe skin is
interlinked. Review ofthe current randomized and placebo controlled human trials
reveals that the synergistic use of specific antioxidants proves to be more successful
than with the individual components alone.
fl-carotene in Synergy
The protective effect of oral supplementation with ]3-carotene and vitamin E
against the development of erythema in humans was recently examined alone and in
combinations7. Serum 13-carotene and vitamin E concentrations were found to
increase with oral supplementation. After 12 weeks of treatment with a carotenoid
supplement (25 mg) or carotenoid plus vitamin E (500 IU), the erythema reaction after
UV irradiation was significantly diminished (p<0.01) on dorsal (back) skin. The
authors found that the suppression oferythema was greater when the antioxidants
were used in combination than when the carotenoids were used alone. Weaknesses of
this study include the lack of a placebo group and the absence of blinding ofthe
investigators to the identity ofthe experimental groups.
Another proposed mechanism for the prevention of skin cell carcinogenesis is
to protect cells from the attack of the free radicals, NO)_ and peroxynitrite anion
(OONO-). In a study by Bohm et al., 19985s, human lymphoid cells were taken
before and after patients consumed a 2-week regimen combination of oral ]3-carotene
(150mg/day,), vitamin C (1000mg/day), and vitamin E (ct- tocopherol 800mg/day).
2O
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All cells were then exposed to the free radicals NO2 and OONO-, in sequemial
experiments. Cell staining with eosin was used to show which cells had membrane
destruction leading to cell death. The cells taken from patients after the antioxidant
treatment showed cell staining of 6% while cells taken from patients before
antioxidant treatment had a cell staining of 61.4%. The authors concluded that the use
of [-carotene with vitamins C and E offered synergistic cell protection against both
the NO and OONO- radicals with a greater protective effect against NO2.
Vitamin C and Vitamin E alone and in Synergy
Studies suggest that the topical application of vitamin C combined with
vitamin E offers a more significant photoprotective effect than either agent alone. On a
molecular level, this may be due to the capacity of vitamin C to regenerate vitamin E
from its free radical form.59’60 This premise has been supported by other
investigations that examined the antioxidant interactions on membrane lipid
oxidation.6’62 In effect, by combining vitamin C and E, the free radical scavenging
capabilities of each may be extended, thereby increasing the total antioxidant capacity
of the skin.
Vitamin C, or ascorbic acid, is a cofactor for the enzymes that are responsible
for the hydroxylation of proline and lysine in collagen, which helps to stabilize
collagen’s helical structure.62 The body does not produce this antioxidant; instead it
must be consumed in the form of citrus fruits, strawberries, tomatoes, cantaloupe,
potatoes, and dark green leafy vegetables. Studies by Shindo et al. in 1993 and
199464,65 in murine epidermis and dermis have shown that UV exposure leads to the
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depletion ofvitamin C. As a result, the skin appears to be susceptible to damage by
reactive oxygen species. Inasmuch as vitamin C is a known antioxidant, it has been
studied as a therapeutic means to protect the skin against free radical damage.
Porcine studies examining the use of vitamin C as a topical photoprotectant
have shown it to concentrate in the skin while decreasing erythema and UVB
phototoxic damage.66 Studies in mice have also shown vitamin C to offer a
photoprotective effect against UV induced chronic skin damage.67
Miyai, 19966 examined the ability of a stable derivative of ascorbic acid,
ascorbic acid 2-O-alpha-glucoside (AA-2G), to induce resistence against UVB cell
injury in a human keratinocyte cell line established from squamous cell carcinoma.
Cells were preincubated in the AA-2G solution, exposed to UVB radiation and then
reincubated in the same solution for 24 hours. Miyai found that the stable ascorbic
acid derivative AA-2G had a significant preventive effect against UVB cellular
damage and this effect had greater significance with increasing concentrations from
0.1 to lmM (p<0.01, p<0.001, p<0.0001) when compared with ascorbic acid or
controls, thereby offering a photoprotective effect against UVB-induced damage in
human epithelial cells.
However, few human double-blind placebo-controlled studies have shown
either topical or oral administration of vitamin C alone to offer photoprotection against
damaging UV radiation. One small study by Murray et al., abstract 1991,69 examined
the effect ofUVB radiation on the forearms of 10 human volunteers who were
pretreated with 10% topical vitamin C solution or placebo. The areas of skin that were
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pretreated with the vitamin C solution demonstrated a less intense erythematous
response while demonstrating a significant increase in the minimal erythema dose.
Vitamin E is found in foods such as nuts, vegetable oils, shortening, margarine,
whole grains, olives, asparagus, spinach, and mayonnaise. Vitamin E is the main lipid
soluble antioxidant that has been shown to protect cell membrane lipids from
peroxidation by scavenging free radicals.6 The topical application of alpha-
tocopherol, the most active form of vitamin E, has been shown to prevent skin cancer
and immunosuppression induced by UVB irradiation in mice.7 However, alpha-
tocopherol has limited stability at room temperature in comparison with the
thermostable esters of vitamin E, alpha-tocopherol acetate and alpha-tocopherol
succinate7. Commercially, the most common form of vitamin E, alpha-tocopherol
acetate, is a popular ingredient added to skin lotions, sunscreens, and cosmetic
preparations. It should be noted that the topical application of the different forms of
vitamin E (including alpha-tocopherol, alpha-tocopherol acetate, alpha-tocopherol
methyl ether, gamma-tocopherol, and delta-tocopherol) has demonstrated varied
results in animal models. For example, mice topically treated with a 1% alpha-
tocopherol and exposed to UVB had 43% less formation ofthymine dimers than
controls. Other forms of vitamin E (including alpha-tocopherol acetate, alpha-
tocopherol methyl ether, gamma-tocopherol, and delta-tocopherol) also inhibited DNA
thymine dimer formation but were 5 to 10 fold less potent than alpha-tocopherol.7
Additionally, Mc Vean et al., 199972 compared the efficacy of alpha-
tocopherol to other vitamin E compounds (alpha-tocopherol acetate, alpha-tocopherol
methyl ether, gamma- tocopherol, delta- tocopherol) and 3 commercially available
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sunscreens for their ability to inhibit DNA photodamage in mouse skin in vivo. They
found that application of a 5% solution of either alpha-tocopherol, gamma- tocopherol,
or delta- tocopherol each produced a significant inhibition ofthymine dimer
formation whereas both alpha-tocopherol acetate and alpha-tocopherol methyl ether
did not. In terms of the commercial sunscreens, only the sunscreen agent
octylmethoxycinnamate inhibited dimer formation while the other two agents tested
(ethylhexyl salicylate and oxybenzone) did not. The incorporation of vitamin E into
sunscreen products confers protection against procarcinogenic DNA photodamage.
However, the specific type oftocopherol appears to be determinate of the magnitude
of the prophylactic effect.
Berton et al., 19987 studied the effect of alpha-tocopherol acetate, applied
before or after UV exposure on the inhibition ofUV carcinogenesis in the hairless
mouse compared with vehicle controls. They found that mice that received the alpha-
tocopherol acetate preparation had delayed tumor formation and yield for the first 20
weeks ofthe study but that this effect was lost by week 30. The telomerase activity of
carcinomas in the mice treated with vitamin E was significantly lower than vehicle
controls. Additionally, cyclobutane dimer repair was greater in the alpha-tocopherol
acetate treated groups and tumor suppressor gene p53 expression was maximally
higher after less UV exposure in this group as well. This study therefore supports the
mitigating role of alpha-tocopherol acetate in the initial events of skin carcinogenesis
associated with UV irradiation such as DNA damage. However, it has limited
potential in preventing UV- induced proliferation and tumor formation.
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Gensler, 199670 examined whether the thermostable esters of vitamin E, alpha-
tocopherol acetate and alpha-tocopherol succinate prevented skin cancer or
immunosuppression in mice. They found that neither of the esters significantly
prevented photocarcinogenesis nor prevented the induction by UV radiation of
immunosusceptibility to implanted antigenic UV-induced tumor cells. Additionally,
they noted that at the concentrations of 12.5mg alpha-tocopherol acetate and 25mg of
alpha-tocopherol succinate, photocarcinogenesis was actually enhanced (p=0.0114).
They concluded that these esterified forms (alpha-tocopherol acetate and alpha-
tocopherol succinate) do not prevent carcinogenesis and may actually enhance skin
cancer development and growth in a UVB carcinogenesis mouse model.
Additionally there has been further research into whether Vitamin E in the
form of alpha-tocopherol acetate was converted in human skin to the active and
photoprotective alpha-tocopherol. In a double-blind study, 19 patients >30 years of
age who had a least three actinic kerotoses on their forearms were randomly assigined
to the treatment group (alpha-tocopherol acetate) or vehicle control group. Both
groups applied the creams to their arms twice daily for three months. Blood samples,
photographs, and punch biopsies were taken before the start of the study and after the
study was completed. Plasma and skin concentrations of free alpha-tocopherol and
alpha-tocopherol acetate were calculated. The investigators found that while alpha-
tocopherol acetate was substantially absorbed in the skin, there was no evidence of
cutaneous or systemic conversion to the active alpha-tocopherol form of vitamin E74
Additionally, the authors surveyed commercially available sunscreens to assess their
alpha tocopherol content and found that of 191 sunscreens sampled, 119 (62%)
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contained some form of alpha-tocopherol, 69 (36%) contained no alpha-tocopherol,
and only three (2%) disclosed the active ingredients.
In light of the Gensler, 199670 and the Alberts et al. 199674 studies, it is evident
that alpha-tocopherol acetate, the most commercially available form of topical vitamin
E, confers less photoprotective effects in mice models than other forms of vitamin E
such as alpha-tocopherol and may even promote carcinogenesis. Additionally, alpha-
tocopherol acetate is substantially absorbed in the skin and is not converted to its
active form. These findings underscore the importance of determining which forms of
vitamin E inhibit the UV induced lesions involved in photocarcinogenesis and which
may actually lead to cancer formation.
Similarly to topical vitamin E, the potencies of several forms of oral vitamin E
vary as well. Dosage is therefore usually expressed in terms of international units
(IU), based on terms of activity. For example, Img d-alpha tocopherol- 1.49 IU. In
humans, a small double-blind placebo-controlled study of 12 patients given oral
vitamin E (not otherwise specified) 400 IU/day for 6 months was not shown to reduce
the MED or the number of sunburn cells when the treatment group was compared to
controls.7s Additionally, Vural, 199976 investigated whether levels of certain plasma
*antioxidant alpha-tocopherol, ascorbic acid, total thiol groups, ceruloplasmin, urate,
albumin, and erythrocyte glutathione, were altered in patients with actinic kerotoses
(AKs) or BCCs. Plasma samples from 13 patient with AKs, 12 patients with BCCs
and 16 healthy controls were compared. Plasma levels of ascorbic acid (p<0.001),
alpha-tocopherol (p<0.05) and RBC glutathione (p<0.05) were significamly lower in
patients with AKs and BCCs. The investigators suggested that plasma levels of
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certain antioxidants were decreased in patients with AKs or BCCs due to the long
exposure ofUV irradiation.
In a double-blind placebo- controlled study, Eberlein-Konig et al., 199877
assessed the photoprotective effect of systemic vitamins C and E in humans. Ten
subjects were randomly assigned to the vitamin group and given daily doses of
vitamin C (ascorbic acid 2g) and Vitamin E (d-alpha-tocopherol 1000 IU) for 8 days,
while the other randomly assigned ten subjects, matched to the first group by skin
type, were given the placebo. The sunburn reaction was assessed by determining the
MED and by measuring cutaneous blood flow of irradiated skin and nonirradiated skin
before and after administration ofthe oral vitamins or the placebo. The results of the
study illustrated that the patients given the oral vitamin combination had significant
increase in their MED (p<0.01) vs. patients in the placebo group. Cutaneous blood
flow was significantly decreased in the treatment group, whereas it was increased in
the placebo group (p<0.05). The authors concluded that the combined use of oral
vitamin C and vitamin E created a synergistic effect to reduce sunburn reactions
significantly.
A second prospective, randomized and placebo controlled human trial by
Fuchs and Kern, 19987 examined whether oral supplementation with vitamin E (d-
alpha-tocopherol) and vitamin C (L-ascorbic acid) alone or in combination influenced
the UV radiation induced skin inflammation in volunteers before and 50 days after
supplementation. A dose-response curve ofUV induced erythema was generated and
the MED was determined by visual grading before and after supplementation. The
dose response curve showed a significant flattening while the MED showed a
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significant increase for the group that received combined antioxidant therapy as
opposed to the groups that received either the vitamins alone or the placebo. The
authors concluded that the antioxidant vitamins E and C acted synergistically in the
suppression of the sunburn reaction.
Dreher et al. 1998s9 recently investigated the possible photoprotective effect
achieved when topical vitamin C, vitamin E, and melatonin were combined in a small
randomized, double-blind human study. Twelve patients of Fitzpatrick skin type II or
III were selected and all patients served as their own respective controls. All patients
received combinations of the antioxidant mixtures and vehicle controls, which were
applied to the lower backs ofthe patients in a randomized double-blind manner.
Thirty minutes after treatment, all patients were subjected to UV radiation and their
response was measured in terms of Frosch and Kligman (1979)79 erythema scale. The
authors found that the topical application ofthe hormone melatonin alone resulted in a
dose-dependent inhibition ofthe erythema formation. The use ofvitamin C or E alone
had only a slight effect on the amount of erythema demonstrated by the patients. The
combination ofvitamin C and E showed a more prominent effect in erythema
prevention while the combination of vitamin C, E, and melatonin had a significant
inhibitory effect on erythema.
In conclusion, the skin has an endogenous complex antioxidant defense
system that scavenges reactive oxygen species and combats UV-induced oxidative
skin damage. This defense system, however, can become overwhelmed with
excessive UV exposure, which leads to cutaneous UV damage, premature aging and
skin cancer,s Supporting the naturally occurring antioxidant system ofthe skin via
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delivery of antioxidants either topically or orally may be a successful strategy for
photoprotection.
Effects of Fat Intake on NMSC
Black and colleagues,19948 studied the relationship between fat intake and the
development of actinic keratoses (AKs) and NMSC. In an initial randomized clinical
trial 76 patients with a history ofNMSC were asked to eat their regular diets (control
group) or a modified diet with 20% of their total calories derived from fat (the
experimental group).8 For a total of 24 months the patients were examined by a
physician, blinded to the designation of the study groups, for the development of
actinic keratoses. At four months of dietary intervention the control group maintained
their fat intake at 40% of their total calories while the experimental group had lowered
their fat intake to 20% of their total calories. The total number ofAKs per patient
over the study period was significantly fewer in the experimental group than in the
control group.
A further clinical trial by Black et al. 199882 involving 115 patients who were
randomly assigned to either the control or experimental group examined the
relationship between a low fat diet and the prevention of actinic keratoses and NMSC
over a two-year period. In this study the patients in the experimental group were
educated in detail regarding dietary changes in order to reduce their fat intake to 20%
of their total calories and maintain this change over the entire two-year period. The
results of this study were similar to the Black et al., 1994 study, in that there was a
significant decrease in the skin cancer occurrence of the experimental group as
compared with controls (p<0.01). The cumulative numbers ofnew AKs per patient
over the 2 years was significantly (p<0.001) fewer in the experimental group than in
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the control group. There were no significant changes in the numbers ofNMSC skin
cancers per patient in the control group over the 2-year period. However, in the
experimental group the numbers ofNMSC decreased significantly over the last 8
months ofthe study (p<0.02). The authors did not postulate a specific reason for this
interesting finding in the study’s final 8 months instead of at earlier time periods
during the study.
Herbal and Alternative Therapies for NMSC
Anticarcinogenic Effects ofTea
Chemoprevention by means of phytochemicals has been the focus ofmany
cancer prevention studies within the last decade. In many cultures, the most popular
beverage in the world, next to water, is tea. Many animal organ specific studies have
shown that certain components of tea offer anti-carcinogenic properties. These
constituents are known as polyphenols, which serve as antioxidants to prevent
oxidative damage induced by free radicals.83 Studies have focused on the phytogenic
properties of green tea polyphenolic (GTPs) antioxidants and have recently been
reviewed in Katiyar et al., 2000. 84 The major and most preventive ingredient thought
to confer the cancer chemopreventive properties of green tea is known as
(-)-epigallocatechin-3-gallate (EGCG).8
There are increasing amounts of experimental evidence both in animal and
human studies that indicate that both topical and systemic extracts of green and black
86tea can inhibit carcinogenesis. Animal studies have shown both chemically and UV
induced cutaneous carcinogenesis has been inhibited by the phytochemicals available
in tea.87’88 Agarwal et al. 199289 studied the effect of topical application of EGCG to
the skin of SENCAR mice pretreated with TPA, a tumor promoter. They found that
there was a dose-dependant reduction in epidermal inhibition of ornithine
decarboxylase, an enzyme responsible for clonal expansion of skin tumors. Studies
involving black tea polyphenols have elicited similar results in the inhibition of the
tumor promoter TPA.9 Green tea polyphenols (GTP), applied to DMBA/TPA
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induced cutaneous papillomas have been shown to inhibit the conversion of benign
neoplasms to malignancies in SENCAR mice. Mice with pre-existing papillomas
were exposed to additional free radical generating compounds such as benzoyl
peroxide or 4-nitroquinoline-N-oxide to initiate a malignant conversion. The
formation of squamous cell carcinomas from papillomas was significantly reduced
with administration of GTP 30 minutes prior to application of the free radical
generating compounds.9
In an in vivo study by Gensler et al. 199692, topical EGCG was applied 3 times
per week to BALB/cAnNHsd mice in doses of 0mg, 10mg, or 50mg for 28 weeks
while they concurrently received 2. lx 106 J/m2 ofUVB light 5 times per week. The
incidence, multiplicity and volume ofUV-induced skin tumors were significantly
reduced in a dose dependant manner in these animals.
The protective effect of topically applied GTP against UV induced erythema
has been studied in human volunteers by Mukhtar et al., 1996.93 Different
concentrations of green tea polyphenol preparations, as well as a placebo dose, were
applied to the backs of volunteers who were then subjected to UV radiation at twice
the minimal erythema dose (MED). Sites that were pretreated with the GTP solutions
exhibited significantly less erythema than the controls. The photoprotective effect of
GTP was dependent on the strength of the dose applied with the most effective
protection seen at dose of 200/al of a 5% solution.
A significant protective effect against MED enhancement of sunburn cell
formation was also reported. A more recent human study by Katiyar et al., 199994
examined whether topical treatment with EGCG would offer protection against UVB-
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induced infiltration of leukocytes, a possible source of oxygen radical generation and
prostaglandin metabolites which have been shown to play a prominent role in skin
carcinogenesis. The authors found that application oftopical EGCG prior to UVB
exposure significantly blocked the infiltration of leukocytes, led to decreased
erythema, and produced fewer intlammatory prostaglandin metabolites. Additionally,
the topical application of GTPs before UVB exposure ofhuman skin led to a
decreased formation of cyclobutane pyrimidine dimers in DNA, which have been
implicated as initiators in the process ofUV induced mutagenesis and
carcinogenesis.84,94
As described above, there is much animal and human evidence pointing to the
use oftea as a phytogen to help to boost the endogenous antioxidant defense system of
the skin. Randomized clinical placebo-controlled trials on human subjects are now
required to evaluate the efficacy of naturally occurring polyphenols found in tea.
Current Phase I Clinical Trials are now underway at M.D. Anderson Cancer Center
and Memorial Sloan-Kettering Cancer Center on the therapeutic effect of green tea on
advanced solid tumors.8
Other Herbal and Alternative Treatmentsfor NMSC
A myriad of small studies examining the relationship between herbal and
alternative remedies for the treatment and prevention ofNMSC have been published
in the oncology literature and are summarized in table 1.
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Table 1. Herbal and alternative remedies for the treatment and prevention of
Study
1
Hibatallah
et al.,
199995
2 Lin &
Chang,
199796
3 Guevara
et al.
199997
Seed or
Herb
Ginkgo
biloba
Ginkgo
biloba
Seeds of
the
Philippin
e Plant-
Moringa
oleifera
Lain
"Horse
radish"
Ginseng
Active
Ingredient
33% extract of
Gingko flavone
gycosides
Ginkgo biloba
Extract in 50%
alcohol
Niazimicin
Methanol extract
of heat-
processed
ginseng
NMSC.
Experimental
Milieu
In vitro and In
vivo (human
models)
In vivo (mouse
models)
In vivo (mouse
models)
4 Keum et
al., 200098
In vivo (mouse
models)
Mechanism
of Action
Gingko biloba
is 24%
flavenoids,
which has the
properties of a
free radical
scavenger
similar to
superoxide
dismutase.
Locally induce
superoxide
dismutase and
catalase
enzyme
activity in
epidermis of
rats
Mechanism not
specified
TPA-induced
enhancement
of epidermal
ornithine
decarboxyase
activity and
mRNA
expression was
abolished
Findings
Ginkgo extract
significantly
inhibited the
cutaneous
blood flow by
37% (which
reflects the
skin
inflammatory
level)
Ginkgo biloba
pre-treated
skin showed
significant
protection
against UVB
damage
Niazimicin has
a potent
antitumor
promoting
activity against
the two stage
mouse tumor
carcinogenesis
model (DMBA
as a tumor
initiator and
TPA as a
tumor
promoter)
Significantly
decreases the
formation of
skin
papillomas
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NMSC.
Cruciferous
vegetables:
cabbage,
cauliflower,
and brussel
sprouts
Indole-3-carbinol In vivo (mouse
models)
5
Srivastava
& Shukla,
199899
A single dose of
the tumor
initiator DMBA,
followed by the
tumor promoter,
TPA twice per
week. Half of
the mice
received 250 ug
indole-3-
carbinol.
6
Yasukawa,
19981
Rice bran Cycloartenol
ferulate
In vivo (mouse
model)
Pharmacological
activities ofthe
ferulate
components of
rice bran
include:
improves
peripheral blood
flow, possesses
anti-
inflammatory
effect, possesses
anti-tumor
promoting effect
Tumor
development
was
significantly
inhibited in
indole-3-
carbinol-
supplemented
animals in
terms of
cumulative
numbers of
tumors and
average
tumors per
mouse. 44%
of the male
mice and 29%
of female mice
remained
tumor free by
the end of the
experiment. A
significant
delay in tumor
induction time
was also
observed in
indole-3-
carbinol
supplemented
animals
Dose
dependant
inhibition of
DMBA/TPA
tumor
induction and
inflammation
in mice
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7
Ichihashi,
2000TM
8 Zhao et
al.,
199912
NMSC.
9 Gensler
et al.,
199913
Extra Extra virgin In vivo (mouse Possibly by Olive oil painted on
virgin olive oil model) decreasing the skin after UVB
olive oil reactive oxygen exposure
species induced significantly
8-OhdG, which delayed the onset
is responsible and reduced the
for gene number of skin
mutation cancers. 8-OHdG
formation in mice
was inhibited
Grape Grape seed In vitro The The observed anti-
seeds polyphenols SENCAR polyphenols tumor-promoting
(GSP) mouse skin isolated effects of GSP were
significantly dose dependent and
inhibited resulted in a
epidermal lipid reduction oftumor
peroxidation incidence,
multiplicity and
volume
Niacin Vitamin B3 In vivo mouse Niacin A do’se-dependent
model supplementation preventive effect of
elevated skin oral niacin on
NAD content, photocarcinogenesis
which is known and photo-
to modulate the immunosuppression
function of
DNA strand
scission
surveillance
proteins p53
and poly(ADP-
ribose)
polymerase, two
proteins critical
in cellular
responses to
UV-induced
DNA damage.
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10 Huang
et al.,
1994TM
11
Limtrakul
et al.,
199755
Rosemary
The pl’nt
Curcuma
longa
Milk
Thistle
Carnusol/ursolic
acid
Curcumin, the
yellow pigment
used as a spice
and food
coloring agent
The flavonoid
Silymarin
NMSC
In vivo mouse
model
In vivo mouse
model
12 Lahiri-
Chatterjee
et al.,
1999506
SENCAR mouse
model
Not specified
Curcumin is a
phenolic
compound
possessing
anti-
inflammatory
and anti-
oxidant
properties that
inhibit DMBA
initiated TPA-
induced
epidermal
DNA
synthesis.
Highly
significant
dose-
dependent
inhibition of
tumor DNA
synthesis and
lipid
peroxidation
Topically
applied
rosemary
inhibits skin
tumor
initiation by
DMBA, tumor
promotion by
TPA
Dietary
administration
of curcumin
significantly
inhibited the
number of
tumors per
mouse
(p<0.05) and
the tumor
volume
(p<0.01)
Application of
silymarin prior
to
DMBA/TPA
significantly
reduced tumor
incidence
(p<0.001),
tumor
multiplicity
(p<0.001) and
tumor volume
(p<0.001)
Melanoma Sn Cancer
Evidence supports the concept that UV radiation induces DNA damage that
leads to melanoma in both animal and human skin.7 For example, patients with
xeroderma pigmentosum have a decreased ability to repair DNA damage caused by
UV radiation and have a greater risk of developing both melanoma and non-melanoma
skin cancer. Additionally, it was recently shown that melanoma could be induced via
UV radiation exposure on human skin in an experiment conducted with human skin
xenographically attached to immunologically naive mice.8 The incidence of
melanoma skin cancer increases exponentially with age. 09 The opport.Nnities for the
generation oftumors over time are increased in addition to the decrease in the ability
to repair DNA. 0
UVB radiation is significantly responsible for the formation of the main DNA
lesions and also the formation of photoproducts such as cyclobutane pyrimidine
dimers and pyrrimidine (6-4) pyrimidone photoproducts.7 The incorrect repair of
these principal DNA lesions leads to mutations. A significant contributor to the
formation ofmelanoma is intense intermittent exposure to UV radiation7. In
accordance with this hypothesis, although melanoma can occur at any location on the
body, it most commonly affects areas of intermittent sun exposure such as the upper
107,110,Illbacks ofmen and the lower legs of women.
Melanocytes, unlike keratinocytes, do not experience the same level of
apoptotic screening. Although a first high dose ofUV radiation will cause significant
damage to melanocytes, they are much more likely to mutate and survive than
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keratinocytes.7 In contrast, after prolonged UV exposure, the most severely
damaged keratinocytes undergo apoptosis, leaving the less damaged keratinocytes to
up-regulate DNA repair capacity and restore themselves back to their baseline. With
each continued exposure the most damaged cells are removed and the cells with only
minimal damage remain. It has been previously illustrated that these sub-lethal hits to
the DNA of keratinocytes actually promote the DNA repair mechanisms ofthe
cells.5,1
Phytochemicalsfor MMPrevention
Mice studies have examined a variety of dietary supplements that may prove to
be helpful in the prevention of cutaneous melanoma and the metastasis ofmelanoma.
Plant estrogens or phytoestrogens have been investigated for their anticancer effects.
Recently, Li et al. 1999 looked at the importance of lignans, a group of
phytoestrogens, which are converted in humans to enterodiol and enterolactone by the
action of the bowel microflora. Lignan precursors are found in oilseeds, whole grains,
legumes and certain vegetables, but flaxseed is the richest source. Evaluation ofthe
effect of dietary supplementation with a flaxseed derivative known as
secoisolariciresinol diglycoside (SDG) on the metastasis ofmelanoma in mice
demonstrated a reduction in the volume and number ofpulmonary melanoma
metastases as compared to the control group (P< 0.01). 13
Studies of the murine melanoma cell line B 16 and specific phytochemicals
have illustrated a tumor growth-suppressive effect. Mo and Elson 1999 14 examined
the relationship between the isoprenoids, fl-Ionone (a cyclic analog of 13-carotene) and
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gamma- tocotrienol (a less potent form ofvitamin E) isolated from rice bran oil on the
murine melanoma B 16 cell line. They found that the addition offl-ionone and
gamma-tocotrienol to the tumor cell lines led to a 23% inhibition in growth (p<0.001
for 15umol/L) and a 56% inhibition in growth (p<0.001 for 150umol/L) ofthe
melanoma cells, respectively. The study also illustrated a synergistic and additive
growth-suppressive action on the melanoma cells when these phytochemicals were
combined.TM
Vitamin D
Vitamin D is found in fortified milk, fish (herring, mackerel, salmon, sardines,
shrimp, tuna, cod), fish oil, and is also produced in the skin by UV induced conversion
ofprevitamin D. Vitamin D is then hydroxylated in the liver and kidney respectively
to its most active form 1,25-dihydroxyvitamin D3 (VD3). This active steroid hormone
binds to the vitamin D receptor (VDR) to exert its actions, including calcium
homeostasis. VDR has also been detected in certain cancer cell lines including
melanoma. 16 A panel of eight human melanoma cell line was assessed for the level
ofVDR expression and the growth inhibitory effects ofVD3 by Evans et al. 1996. 115
VDR expression was illustrated in the various melanoma cell lines. Furthermore,
VD3 was a significant (P<0.05) melanoma growth inhibitor in cells with a high
concentration of the VDR receptor. The authors concluded that melanoma cell growth
inhibition might be mediated through the VDR receptor concentration.
Additionally, the role of VD3 and its derivatives on the induction of
programmed cell death, or apoptosis, for human melanoma cells has been examined
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by Danielsson et al., 1998. 17 VD3 has been shown to induce apoptosis in human
breast cancer and leukemic cell lines, l8 In spite of the fact that VD3 has therapeutic
potential, its side effects such as hypercalcemia, hypercalciuria and soft tissue
calcification make it impractical to use clinically. 117,119 VD3 analogs with molecular
modifications have therefore been created. The VD3 analog CB1093 has been
examined as a future treatment against specific types ofmelanoma inasmuch as it was
previously found to induce apoptosis of rat mammary tumors in vivo at a lower
concentration than other VD3 analogs with fewer calcemic side effects. Danielsson
et al., 19987 reported that in the early melanoma stage cell line WM1341 apoptosis
was induced by CB1093 up to twentyfold after 5 days oftreatment at a tenfold lower
concentration than the natural hormone (VD3). In contrast, CB1093 was not effective
against the advanced stage MeWo melanoma cell line. In conclusion, the 1,25-
dihydroxyvitamin D3 analog, CB 1093, may serve as a promising therapeutic
intervention for in vivo regression of ihe early stages ofmelanoma without the severe
calcemic side effects of its natural vitamin D counterpart.
In further studies, the role ofvitamin D and select retinoids on the induction
of apoptosis of human melanoma cells has been examined by Danielsson et al.,
1999.2 The combined treatment of Vitamin D3 with the select retinoid receptor
ligand CD437 resulted in a synergistic induction of apoptosis for the specific human
melanoma cell line WM1341. In contrast, combination therapy did not induce
apoptosis in the MeWo cell line. The authors concluded that each type of melanoma
cell line has an individual response to combined treatment with vitamin D and select
retinoids.
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Reactive Oxygen Species
As previously discussed, the delicate balance between free-radical generation
and free radical scavenging systems is monitored by the skin’s endogenous defense
system which combats free radical induced cellular damage and death. An imbalance
in antioxidant levels was found in certain cultures of melanoma cells and normal
melanocytes from patients with melanomaTM This disequilibrium included higher
levels of polyunsaturated fatty acids, a decreased level of catalase activity, and
increased concentrations of superoxide dismutase and vitamin E in cells from
melanoma patients.
In a recent study by Grammatico et al., 19982, the intracellular levels of
catalase, superoxide dismutase, and vitamin E in normal melanocytes from 11 patients
with melanoma were compared with normal melanocytes from 11 controls. The
percentage of unsaturated fatty acids of cell membranes after exposure to a
peroxidizing agent was measured as a means of determining the amount of free radical
lipid peroxidation damage. A significant decrease (P<0.001) in the catalase level was
associated with an increase in the vitamin E concentration in 5 out of the 11 cultures
from melanoma patients as compared with the controls. No significant change of
superoxide dismutase activity was found. The percentage of unsaturated fatty acids of
cell membrane peroxidation was affected by the ratio of superoxide dismutase to
catalase and increased in melanocytes from melanoma patients vs. controls. The
authors concluded that an imbalance in the free radical scavenging system ofthe skin
could be present in normal melanocytes from melanoma patients and this may be the
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reason for the increased susceptibility to pro-oxidizing agents such as reactive oxygen
species.
Dietary Supplements
The relationship between diet and the risk of developing melanoma has been
examined in human case-control studies over the last decade. For example, a study
conducted at the Massachusetts General Hospital included 165 melanoma patients and
209 controls. Both populations were controlled for age, hair and eye color, and family
history ofmelanoma. No significant associations were found between the total
amount ofvitamin D intake from food, supplements or milk and the risk of developing
melanoma in the case versus control populations.3
Kirkpatrick et al. 199424 assessed intakes of vitamin A, dietary antioxidants,
and other dietary nutrients and their relationship to the risk of developing melanoma in
a case-control study. Patients with a history ofmelanoma were randomly selected
from the Seattle-Puget Sound cancer registry and 234 cases were matched to 248
controls for age, sex, and county. All subjects completed a telephone interview and
mailed in food questionnaires in which they were asked to estimate their food intake 7
years prior to diagnosis for melanoma patients and a similar time period for controls.
They found that the level ofvitamin E obtained from food was inversely related to the
risk of developing melanoma at an age, education, and energy intake adjusted odds
ratio (OR 0.34, and P=0.01). Additionally, zinc from food supplements was
associated with a decreased risk ofmelanoma (OR=0.46, and P=0.01). There were no
correlations found with the levels of vitamin A, retinoids, carotenoids and the risk of
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melanoma. There was also no increase in the risk of developing melanoma with
increased alcohol or polyunsaturated fat consumption. In contrast, body mass index
was significantly related to melanoma risk as melanoma patients were more obese
than controls after both populations were age, sex and education adjusted (OR= 1.90,
and P=0.02). The authors point out the important confounders of this study including
a possible recall bias of the cases who may have been hypervigilant in recalling their
diets previous to diagnoses oftheir respective melanomas. In addition, the validity of
a food questionnaire is always a concern in epidemiological studies; however, other
researchers have substantiated dietary questionnaires of this type. 124 These findings
were similar to the Stryker et al., 1990 case-control study of 204 melanoma patients
compared with 248 controls in terms ofthe plasma levels of retinol, vitamin E, and B-
carotene and the lack of correlation of melanoma. However, the Stryker et al., 1990
study found a significant correlation between the amount of alcohol consumed and the
risk of developing melanoma (OR=l.8, 95% confidence interval and P=0.03).
Another case-control study examining the correlation between prediagnostic
serum levels of retinol, B-carotene, vitamin E, and selenium and the subsequent risk of
developing melanoma was conducted by Breslow et al., 1995.26 Serum retinol, B-
carotene, vitamin E, and selenium were assayed to determine the concentration of
these nutrients in case and control samples. Results showed no significant differences
in the serum concentration between the cases or controls. No beneficial influence of
serum nutrients was elicited on the risk of developing melanoma.
The dietary factors and the risk of developing melanoma have also been
studied in a prospective large human cohort study on 50,757 Norwegian men and
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women. All patients in the study completed self-administered dietary questionnaires
previously tested for their validity and reproducibility. The questionnaire did not
focus on the intake of nutrients such as carotenoids, retinoids or vitamin C or E, hence
no broad range of vegetables or fruits were taken into account. The study focused
more on foods such as milk, potatoes, bread, jam, cheese, meat, fats on bread, fats in
cooking, fish, cakes, eggs, oranges, porridge, cod liver oil and vitamin pills. 27 They
found that over the study period from 1977 to 1992, 108 cases of cutaneous melanoma
were identified. Of the 47 cases found in men, most were found on the trunk,
whereas ofthe 67 cases found in women, most were on the lower limbs. This study
found a higher incidence of the development ofmelanoma in women who had a higher
intake of polyunsaturated fats and cod liver oil supplements. The intake of caffeine
for women was inversely related to the development ofmelanoma. There were no
significant correlations for the men in the study. As the authors point out, the
strengths of this study are the high number of participants, the high response rates of
the participants and the prospective design including thorough follow-up. The results
were somewhat surprising as cod-liver oil is high in omega-3 fatty acids, which have
been previously linked to the inhibition ofUV-carcinogenesis, the decreased risk of
lung cancer, and a protective effect against breast and colon cancer.2’9’3 It should
be noted, however, that no other study has examined the relationship of cod liver oil to
melanoma.
In agreement with the Veierod et al.,19977 study, one Danish case-control
study illustrated a decreased incidence ofmelanoma with increased coffee intake. TM
Other studies examining this relationship have not concurred with these results. 32’33
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Similar discrepancies exist among studies examining the relationship between
melanoma and polyunsaturated fats. 134,135,136
Discussion
Primary and secondary prevention of skin cancer remain two essential ways to
curb the increasing incidence of skin cancer in our population. Physical examination
ofthe skin and biopsy of all suspicious lesions is still the mainstay of decreasing the
morbidity and mortality of skin cancer.
Of note, in the last decade, the patient population has shown an increased
interest in the use of dietary supplements such as vitamins and herbal preparations to
attempt to prevent cancer. In a recent mail survey of 1,035 people, 40% of
respondents reported the use of some form of alternative health care during the prior
year.6 Ofthe four alternative treatments most commonly used, dietary changes or
changes in "lifestyle diet" were the second most frequently reported.6
Public health advocates need evidence-based information about the effects of
dietary intake and topical applications of antioxidants, vitamins, and herbal remedies
in order to make sound treatment decisions for the care of their patients. In terms of
NMSC, review of recent randomized clinical trials, large human cohort studies, and
case-control studies does not substantiate a beneficial effect for either natural dietary
retinoids or synthetic retinoid supplementation for treatment or prevention of BCCs or
SCCs in the general population. Select populations with defective DNA repair
mechanisms, immunosuppression, or psoriasis receiving PUVA have been shown to
significantly benefit from systemic retinoid treatments. Additionally, while oral
administration of selenium has shown promise for reducing the incidence of several
types of cancer, its direct effect in reducing BCC or SCC incidence has not been
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demonstrated. No protective effect for NMSC was achieved with either normal
dietary consumption or oral supplementation of -carotene23’47’4g’49.
However, substantial evidence indicates that the cutaneous antioxidant system
is both synergistic and mulifactorial. Review ofthe current randomized human
clinical trials reveals that the synergistic use of specific antioxidants proves to be more
successful than with the individual components alone. The use of [3-carotene with
vitamins C and E offered synergistic cell protection against both the NO2 and OONO-
radicalss In a double-blind placebo-controlled study, the combined use of oral
vitamin E (d-alpha-tocopherol) and vitamin C (L-ascorbic acid) created a synergistic
effect to reduce sunburn reactions significantlys’7’7 In summary, the skin has an
endogenous complex antioxidant defense system which can become overwhelmed.
Delivery of antioxidants in combination may serve as a successful strategy for
enhancing the natural antioxidant system ofthe skin.
The most commercially available form of an antioxidant may not necessarily
be the best form for the treatment of patients. This fact has been highlighted by the
Gensler, 1 99663 and the Alberts et al., 1 99667 studies which emphasize the importance
of determining which forms of vitamin E can inhibit photocarcinogenesis and which
forms may actually lead to cancer formation. Moreover, in order to gain the
photoprotective benefits from vitamin C, it is essential that the type of ascorbic acid
used must be able to penetrate the skin and deliver L-ascorbic acid. Patients should
be advised that many cosmetic vitamin C based products available in the commercial
market contain ineffective derivatives and analogs of ascorbic acid. 153
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In terms ofherbal remedies for NMSC, the phytogens available in tea have
been shown to help boost the endogenous antioxidant defense system ofthe skin in in
vitro mouse and human cell lines and in in vivo mouse models. However, randomized
clinical placebo-controlled trials on human subjects are required to evaluate the
efficacy ofthe naturally occurring polyphenols. Also, many single studies in mice and
humans have elaborated potential new antioxidants for the treatment and prevention of
NMSC including ginkgo biloba, ginseng, horseradish, rosemary, and milk thistle.
Results from human case-control and large cohort studies examining dietary
intake or vitamin supplementation for the treatment and prevention ofmelanoma have
not been consistent. In studies with specific melanoma cell lines there appears to be
promise for the 1,25-dihydroxyvitamin D3 analog, CB1093, as a therapeutic
intervention for in vivo regression ofthe early stages of melanoma without the severe
calcemic side effects of its natural vitamin D counterpart 0.
Conclusion
The increasing incidence of skin cancer in our population has reached
epidemic proportions and has highlighted the need for public health awareness and
intervention. Methods to curtail the rise of skin cancer in the US include the use of
natural alternatives to prevent and treat NMSC and MM. The effectiveness of these
alternative therapies may be supported with further human randomized clinical trails
providing an evidence-based approach toward improving the health of our population.
In this paper, the use of dietary interventions and herbal remedies relating to
the treatment and prevention of skin cancer has been discussed. For the general
population, the natural or synthetic dietary retinoids, selenium or [3-carotene do not
seem to be a clinically protective against NMSC. Current clinical trials reveal that the
synergistic use of specific antioxidants has greater efficacy than the use of individual
components alone.-
In terms of herbal remedies for NMSC, the active herbal extractions available
in tea, ginkgo biloba, ginseng, horseradish, rosemary, and milk thistle have not yet
been shown to be effective for humans
Dietary intake or dietary supplementation for the treatment and prevention of
melanoma, the vitamin D analog, CB 1093 may have promise as a therapeutic
intervention.
Enthusiasm for the use of dietary derived modalities for the treatment and
prevention of skin cancer and is shared by physicians, patients, and the pharmaceutical
industries but needs to be supported by further evidence based studies.
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